Arkolith/Insider Trading/KRYS/Form 4

Thomas John Charles

EVP, General CounselKrystal Biotech, Inc. (KRYS) · full profile →Form 4 · filed Jun 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$347K
Net Open-Market Flow
-$347K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 25, 2026Option exercise(M)1K$179.25$179K1K
Jun 25, 2026Sell(S)1K$347.27$347K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 25, 2026Option exercise(M)1K—$07K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002114900-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML